Literature DB >> 20809711

Surgically treated movement disorders associated with heterotopia: report of 2 cases.

Jeffrey P Mullin1, Jamie J Van Gompel, Kendall H Lee, Fredric B Meyer, Matt Stead.   

Abstract

Heterotopic gray matter has been implicated in epilepsy; however, not much is known regarding heterotopia beyond epilepsy. Here, the authors describe 2 pediatric patients with deep heterotopias contiguous with basal ganglia structures. These heterotopias appear to have manifested as movement disorders. One patient presented with a left-sided myoclonus and choreiform movements associated with a right caudate heterotopia; she experienced vast improvement after resection of periventricular heterotopia. The other patient presented with progressive dystonia and a ballistic movement disorder. Initial bilateral globus pallidus internus stimulation resulted in successful treatment of the dystonia; however, her movement disorder worsened. After an extensive workup, including STATISCOM (statistical ictal SPECT coregistered to MR imaging), the patient underwent cortical stimulation with improvement in her movement disorder. To the best of our knowledge, these cases are the first reported instances of heterotopic gray matter associated with movement disorders. Both patients experienced significant improvements following resection of their heterotopias.

Entities:  

Mesh:

Year:  2010        PMID: 20809711     DOI: 10.3171/2010.5.PEDS10220

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  2 in total

1.  Deficiency of mDia, an actin nucleator, disrupts integrity of neuroepithelium and causes periventricular dysplasia.

Authors:  Dean Thumkeo; Ryota Shinohara; Keisuke Watanabe; Hirohide Takebayashi; Yosuke Toyoda; Kiyoshi Tohyama; Toshimasa Ishizaki; Tomoyuki Furuyashiki; Shuh Narumiya
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

2.  Deep brain stimulation for dystonia.

Authors:  Wei Hu; Matt Stead
Journal:  Transl Neurodegener       Date:  2014-01-21       Impact factor: 8.014

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.